Table 1. Patient characteristics (n=33).
| Characteristics | Values | ||
|---|---|---|---|
| Age (yr) | 60 (33–85) | ||
| Histological subclassification | |||
| Adenocarcinoma | |||
| Endocervical adenocarcinoma, usual type | 15 (45) | ||
| Mucinous carcinoma, NOS | 6 (18) | ||
| Mucinous carcinoma, gastric type | 1 (3) | ||
| Mucinous carcinoma, intestinal type | 1 (3) | ||
| Mucinous carcinoma, signet-ring cell type | 1 (3) | ||
| Endometrioid carcinoma | 3 (9) | ||
| Clear cell carcinoma | 1 (3) | ||
| Unknown | 1 (3) | ||
| Adenosquamous carcinoma | 4 (12) | ||
| Maximum tumor size (cm) | 5.3 (3.4–11.8) | ||
| Stage | |||
| IIB | 13 (39) | ||
| IIIB | 19 (58) | ||
| IVA | 1 (3) | ||
| Lymph node metastasis | 13 (39) | ||
| Total dose of CIRT | |||
| 62.4 Gy (RBE) | 2 (6) | ||
| 64.8 Gy (RBE) | 3 (9) | ||
| 68.0 Gy (RBE) | 6 (18) | ||
| 71.2 Gy (RBE) | 8 (24) | ||
| 74.4 Gy (RBE) | 14 (42) | ||
| Follow-up time (mo) | 33.7 (6.2–177.3) | ||
Values are presented as median (range) or number (%).
CIRT, carbon-ion radiotherapy; NOS, not otherwise specified; RBE, relative biological effectiveness.